vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and Star Equity Holdings, Inc. (STRR). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $56.8M, roughly 1.5× Star Equity Holdings, Inc.). On growth, Star Equity Holdings, Inc. posted the faster year-over-year revenue change (69.0% vs 17.7%). Star Equity Holdings, Inc. produced more free cash flow last quarter ($-9.0M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 29.5%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Artists Equity is an American production company founded by actors and filmmakers Ben Affleck and Matt Damon in November 2022.
IOVA vs STRR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $56.8M |
| Net Profit | — | $-1.7M |
| Gross Margin | 67.4% | — |
| Operating Margin | -84.7% | -0.2% |
| Net Margin | — | -3.0% |
| Revenue YoY | 17.7% | 69.0% |
| Net Profit YoY | — | -192.1% |
| EPS (diluted) | — | $-0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $56.8M | ||
| Q3 25 | $67.5M | $48.0M | ||
| Q2 25 | $60.0M | $35.5M | ||
| Q1 25 | $49.3M | $31.9M | ||
| Q4 24 | $73.7M | $33.6M | ||
| Q3 24 | $58.6M | $36.9M | ||
| Q2 24 | $31.1M | $35.7M | ||
| Q1 24 | $715.0K | $33.9M |
| Q4 25 | — | $-1.7M | ||
| Q3 25 | $-91.3M | $-1.8M | ||
| Q2 25 | $-111.7M | $-688.0K | ||
| Q1 25 | $-116.2M | $-1.8M | ||
| Q4 24 | — | $-585.0K | ||
| Q3 24 | $-83.5M | $-846.0K | ||
| Q2 24 | $-97.1M | $-441.0K | ||
| Q1 24 | $-113.0M | $-2.9M |
| Q4 25 | 67.4% | — | ||
| Q3 25 | 43.0% | 43.0% | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 68.7% | — | ||
| Q3 24 | 46.2% | 50.5% | ||
| Q2 24 | -0.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | -84.7% | -0.2% | ||
| Q3 25 | -140.7% | -3.4% | ||
| Q2 25 | -189.8% | -0.6% | ||
| Q1 25 | -245.8% | -5.4% | ||
| Q4 24 | -117.5% | -0.4% | ||
| Q3 24 | -152.1% | -1.2% | ||
| Q2 24 | -327.6% | -0.5% | ||
| Q1 24 | -16464.6% | -9.0% |
| Q4 25 | — | -3.0% | ||
| Q3 25 | -135.3% | -3.7% | ||
| Q2 25 | -186.2% | -1.9% | ||
| Q1 25 | -235.5% | -5.5% | ||
| Q4 24 | — | -1.7% | ||
| Q3 24 | -142.7% | -2.3% | ||
| Q2 24 | -312.2% | -1.2% | ||
| Q1 24 | -15800.8% | -8.6% |
| Q4 25 | — | $-0.49 | ||
| Q3 25 | — | $-0.54 | ||
| Q2 25 | $-0.33 | $-0.23 | ||
| Q1 25 | $-0.36 | $-0.59 | ||
| Q4 24 | $-0.24 | $-0.21 | ||
| Q3 24 | $-0.28 | $-0.28 | ||
| Q2 24 | $-0.34 | $-0.15 | ||
| Q1 24 | $-0.42 | $-0.95 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $10.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $65.7M |
| Total Assets | $913.2M | $113.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $10.3M | ||
| Q3 25 | $300.8M | $15.4M | ||
| Q2 25 | $301.2M | $16.8M | ||
| Q1 25 | $359.7M | $16.6M | ||
| Q4 24 | $323.8M | $17.0M | ||
| Q3 24 | $397.5M | $15.8M | ||
| Q2 24 | $412.5M | $14.7M | ||
| Q1 24 | $356.2M | $20.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | $6.5M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $698.6M | $65.7M | ||
| Q3 25 | $702.3M | $67.8M | ||
| Q2 25 | $698.5M | $40.1M | ||
| Q1 25 | $767.9M | $39.5M | ||
| Q4 24 | $710.4M | $40.4M | ||
| Q3 24 | $773.5M | $42.9M | ||
| Q2 24 | $768.5M | $42.6M | ||
| Q1 24 | $680.0M | $44.3M |
| Q4 25 | $913.2M | $113.2M | ||
| Q3 25 | $904.9M | $117.1M | ||
| Q2 25 | $907.4M | $55.6M | ||
| Q1 25 | $966.7M | $53.2M | ||
| Q4 24 | $910.4M | $52.6M | ||
| Q3 24 | $991.1M | $52.6M | ||
| Q2 24 | $964.3M | $52.6M | ||
| Q1 24 | $869.8M | $52.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.10× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $-7.3M |
| Free Cash FlowOCF − Capex | $-61.9M | $-9.0M |
| FCF MarginFCF / Revenue | -71.3% | -15.8% |
| Capex IntensityCapex / Revenue | 10.7% | 3.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $-13.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $-7.3M | ||
| Q3 25 | $-78.7M | $-2.7M | ||
| Q2 25 | $-67.4M | $139.0K | ||
| Q1 25 | $-103.7M | $-802.0K | ||
| Q4 24 | $-73.3M | $-2.8M | ||
| Q3 24 | $-59.0M | $1.3M | ||
| Q2 24 | $-98.4M | $-4.3M | ||
| Q1 24 | $-122.3M | $-1.8M |
| Q4 25 | $-61.9M | $-9.0M | ||
| Q3 25 | $-89.5M | $-3.4M | ||
| Q2 25 | $-74.9M | $102.0K | ||
| Q1 25 | $-109.9M | $-808.0K | ||
| Q4 24 | $-77.5M | $-2.8M | ||
| Q3 24 | $-61.3M | $1.3M | ||
| Q2 24 | $-98.9M | $-4.3M | ||
| Q1 24 | $-126.5M | $-1.8M |
| Q4 25 | -71.3% | -15.8% | ||
| Q3 25 | -132.7% | -7.0% | ||
| Q2 25 | -124.9% | 0.3% | ||
| Q1 25 | -222.8% | -2.5% | ||
| Q4 24 | -105.1% | -8.3% | ||
| Q3 24 | -104.6% | 3.4% | ||
| Q2 24 | -317.9% | -12.0% | ||
| Q1 24 | -17685.3% | -5.3% |
| Q4 25 | 10.7% | 3.0% | ||
| Q3 25 | 16.1% | 1.3% | ||
| Q2 25 | 12.4% | 0.1% | ||
| Q1 25 | 12.6% | 0.0% | ||
| Q4 24 | 5.7% | 0.1% | ||
| Q3 24 | 3.9% | 0.0% | ||
| Q2 24 | 1.4% | 0.0% | ||
| Q1 24 | 583.4% | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
STRR
| Revenue From Other Contracts With Customers | $27.6M | 49% |
| Other | $24.3M | 43% |
| Energy Services Segment | $4.9M | 9% |
